Should I buy or sell Progyny stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Progyny in the last year. There are currently 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PGNY shares. View PGNY analyst ratings or view top-rated stocks .

What is Progyny's stock price target for 2024?

10 brokerages have issued twelve-month price targets for Progyny's shares. Their PGNY share price targets range from $43.00 to $57.00. On average, they predict the company's share price to reach $48.30 in the next year. This suggests a possible upside of 47.5% from the stock's current price. View analysts price targets for PGNY or view top-rated stocks among Wall Street analysts .

How have PGNY shares performed in 2024?

Progyny's stock was trading at $37.18 on January 1st, 2024. Since then, PGNY stock has decreased by 11.9% and is now trading at $32.75. View the best growth stocks for 2024 here .

When is Progyny's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our PGNY earnings forecast .

How were Progyny's earnings last quarter?

Progyny, Inc. (NASDAQ:PGNY) issued its earnings results on Tuesday, February, 27th. The company reported $0.13 earnings per share for the quarter, beating analysts' consensus estimates of $0.09 by $0.04. The firm earned $269.94 million during the quarter, compared to analyst estimates of $274.08 million. Progyny had a trailing twelve-month return on equity of 12.64% and a net margin of 5.70%. The firm's revenue was up 26.0% on a year-over-year basis. During the same period in the prior year, the firm earned $0.03 EPS.

What ETFs hold Progyny's stock?

ETFs with the largest weight of Progyny (NASDAQ:PGNY) stock in their portfolio include Alger Weatherbie Enduring Growth ETF (AWEG) , Janus Henderson Small Cap Growth Alpha ETF (JSML) , BNY Mellon Women's Opportunities ETF (BKWO) , SPDR S&P Health Care Services ETF (XHS) , Harbor Corporate Culture Small Cap ETF (HAPS) , Thrivent Small-Mid Cap ESG ETF (TSME) , First Trust Nasdaq Lux Digital Health Solutions ETF (EKG) and AdvisorShares Alpha DNA Equity Sentiment ETF (SENT) .

What guidance has Progyny issued on next quarter's earnings?

Progyny issued an update on its first quarter 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share guidance of 0.330-0.350 for the period, compared to the consensus earnings per share estimate of 0.180. The company issued revenue guidance of $285.0 million-$292.0 million, compared to the consensus revenue estimate of $314.0 million.

What is David Schlanger's approval rating as Progyny's CEO?

25 employees have rated Progyny Chief Executive Officer David Schlanger on Glassdoor.com . David Schlanger has an approval rating of 89% among the company's employees.

What other stocks do shareholders of Progyny own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Progyny investors own include NVIDIA (NVDA) , Alibaba Group (BABA) , Salesforce (CRM) , Marvell Technology (MRVL) , Alteryx (AYX) , Micron Technology (MU) , AbbVie (ABBV) , Home Depot (HD) , Advanced Micro Devices (AMD) .

When did Progyny IPO?

Progyny (PGNY) raised $150 million in an initial public offering (IPO) on Friday, October 25th 2019. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch served as the underwriters for the IPO and Citigroup, Piper Jaffray, SVB Leerink and TPG Capital were co-managers.

Who are Progyny's major shareholders?

Progyny's stock is owned by many different institutional and retail investors. Top institutional investors include Congress Asset Management Co. MA (1.05%), International Assets Investment Management LLC (0.16%), Los Angeles Capital Management LLC (0.05%), Radnor Capital Management LLC (0.04%), NBC Securities Inc. (0.03%) and Financial Management Professionals Inc. (0.00%). Insiders that own company stock include Cheryl Scott , David J Schlanger , Group Holdings (Sbs) Advis Tpg, Jennifer Bealer , Kevin K Gordon , Mark S Livingston , Michael E Sturmer , Norman Payson , Peter Anevski , Robert Michael Floyd and Tpg Gp A, Llc. View institutional ownership trends .

How do I buy shares of Progyny?

Shares of PGNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Top-Rated StocksTop-Rated

NASDAQ:PGNY

Progyny (PGNY) Stock Price, News & Analysis

→ With the “Bitcoin Loophole” you can supercharge the gains by 10x or more (From DTI) (Ad)

Free PGNY Stock Alerts

$33.04

+0.29 (+0.89%)

(As of 09:52 AM ET)

Compare

Today's Range: $32.69
▼
$33.04
50-Day Range: $32.75
▼
$41.62
52-Week Range: $29.44
▼
$44.95

Volume: 27,484 shs
Average Volume: 768,992 shs
Market Capitalization: $3.18 billion

P/E Ratio: 53.29
Dividend Yield: N/A
Price Target: $48.30

Get Progyny alerts:

Progyny MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 47.5% Upside
$48.30 Price Target
Short Interest: Bearish
7.87% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.67
Based on 6 Articles This Week
Insider Trading: Selling Shares
$4.57 M Sold Last Quarter
Proj. Earnings Growth: 38.57%
From $0.70 to $0.97 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.43 out of 5 stars

Medical Sector

129th out of 913 stocks

Miscellaneous Health & Allied Services, Not Elsewhere Classified Industry

3rd out of 7 stocks

4.5

Analyst's Opinion

Consensus Rating
Progyny has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 10 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Progyny has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

1.0

Short Interest

Percentage of Shares Shorted
7.87% of the float of Progyny has been sold short.
Short Interest Ratio / Days to Cover
Progyny has a short interest ratio ("days to cover") of 8.1.
Change versus previous month
Short interest in Progyny has recently increased by 5.32%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Progyny does not currently pay a dividend.
Dividend Growth
Progyny does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for PGNY.

3.7

News and Social Media Coverage

News Sentiment
Progyny has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for Progyny this week, compared to 4 articles on an average week.
Search Interest
8 people have searched for PGNY on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
MarketBeat Follows
10 people have added Progyny to their MarketBeat watchlist in the last 30 days. This is an increase of 11% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Progyny insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,570,131.00 in company stock.
Percentage Held by Insiders
14.30% of the stock of Progyny is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
94.93% of the stock of Progyny is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

3.1

Earnings and Valuation

Earnings Growth
Earnings for Progyny are expected to grow by 38.57% in the coming year, from $0.70 to $0.97 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Progyny is 52.82, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 134.75.
Price to Earnings Ratio vs. Sector
The P/E ratio of Progyny is 52.82, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 182.70.
Price to Earnings Growth Ratio
Progyny has a PEG Ratio of 1.38. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Progyny has a P/B Ratio of 5.68. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Paradigm Press

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

About Progyny Stock (NASDAQ:PGNY)

Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides assistance service programs where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.

PGNY Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PGNY Stock News Headlines

April 4, 2024 | insidertrades.com

Progyny, Inc. (NASDAQ:PGNY) Chairman Sells $37,520.00 in Stock

March 30, 2024 | insidertrades.com

Progyny, Inc. (NASDAQ:PGNY) Chairman David J. Schlanger Sells 71,272 Shares

April 18, 2024 | Paradigm Press (Ad)

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

March 28, 2024 | insidertrades.com

Progyny, Inc. (NASDAQ:PGNY) Chairman Sells $97,777.05 in Stock

March 26, 2024 | insidertrades.com

David J. Schlanger Sells 5,826 Shares of Progyny, Inc. (NASDAQ:PGNY) Stock

April 17, 2024 | finance.yahoo.com

Progyny and Fertility Matters Canada Recognize Canadian Fertility Awareness Week to Advocate for Expanded Access to Family Building Care

April 17, 2024 | globenewswire.com

Progyny and Fertility Matters Canada Recognize Canadian Fertility Awareness Week to Advocate for Expanded Access to Family Building Care

April 16, 2024 | finance.yahoo.com

Progyny, Inc. (PGNY) Interactive Stock Chart - Yahoo Finance

April 18, 2024 | Paradigm Press (Ad)

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

April 10, 2024 | nasdaq.com

Benjamin Graham Detailed Fundamental Analysis - PGNY

April 5, 2024 | investing.com

Progyny CFO sells over $419k in company stock

April 5, 2024 | investing.com

Progyny executive chairman sells $37,522 in stock

April 4, 2024 | globenewswire.com

Progyny and RESOLVE to Honor National Infertility Awareness Week® with Events Spanning Coast to Coast

April 3, 2024 | finance.yahoo.com

Insider Sell: President Michael Sturmer Sells Shares of Progyny Inc (PGNY)

March 30, 2024 | finance.yahoo.com

Executive Chairman David Schlanger Sells 71,272 Shares of Progyny Inc (PGNY)

March 28, 2024 | finance.yahoo.com

Executive Chairman David Schlanger Sells Shares of Progyny Inc (PGNY)

March 18, 2024 | globenewswire.com

Progyny, Inc. to Present at KeyBanc Life Sciences & MedTech Investor Forum

March 16, 2024 | finance.yahoo.com

PGNY Apr 2024 20.000 call

March 16, 2024 | finance.yahoo.com

PGNY Apr 2024 55.000 call

March 16, 2024 | finance.yahoo.com

PGNY Apr 2024 30.000 call

March 16, 2024 | ca.finance.yahoo.com

PGNY Apr 2024 40.000 put

March 15, 2024 | seekingalpha.com

Progyny: Long-Term Outlook Remains Positive, Reiterate Buy

March 15, 2024 | cnbc.com

This overlooked corner of women's health could be a $350 billion market opportunity

March 15, 2024 | msn.com

3 Quality Small Caps Available at a Discount Amid Russell 2000 Correction

March 14, 2024 | markets.businessinsider.com

Truist Financial Reaffirms Their Buy Rating on Progyny (PGNY)

March 11, 2024 | globenewswire.com

Progyny, Inc. to Present at Barclays 26th Annual Global Healthcare Conference

March 9, 2024 | seekingalpha.com

Progyny: Long-Term Thesis Still Intact

See More Headlines

Receive PGNY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Progyny and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/27/2024
Today: 4/17/2024
Next Earnings (Estimated): 5/13/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Miscellaneous health & allied services, not elsewhere classified
Sub-Industry: N/A
Current Symbol: NASDAQ:PGNY
CUSIP: N/A
CIK: 1551306
Web: www.progyny.com
Phone: 212-888-3124
Fax: N/A
Employees: 563
Year Founded: 2008

Price Target and Rating

Average Stock Price Target: $48.30
High Stock Price Target: $57.00
Low Stock Price Target: $43.00
Potential Upside/Downside: +47.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 10 Analysts

Profitability

EPS (Most Recent Fiscal Year): $0.62
Trailing P/E Ratio: 52.82
Forward P/E Ratio: 46.79
P/E Growth: 1.39
Net Income: $62.04 million
Net Margins: 5.70%
Pretax Margin: 6.49%
Return on Equity: 12.64%
Return on Assets: 8.82%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.44
Quick Ratio: 3.44

Sales & Book Value

Annual Sales: $1.09 billion
Price / Sales: 2.89
Cash Flow: $0.65 per share
Price / Cash Flow: 50.38
Book Value: $5.77 per share
Price / Book: 5.68

Miscellaneous

Outstanding Shares: 96,110,000
Free Float: 82,989,000
Market Cap: $3.15 billion
Optionable: Optionable
Beta: 1.48

Social Links

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

Mr. David J. Schlanger (Age 65)
Executive Chairman
Comp: $510.41k
Mr. Peter Anevski (Age 57)
CEO & Director
Comp: $1.01M
Mr. Michael Sturmer (Age 47)
President
Comp: $761.5k
Mr. Mark S. Livingston (Age 58)
Chief Financial Officer
Comp: $693.87k
Ms. Allison Swartz (Age 34)
General Counsel & Secretary
Comp: $173.35k
Mr. Steven Leist
Chief Technology Officer
Mr. James Hart
Vice President of Investor Relations
Ms. Risa Fisher
Chief Marketing Officer
Ms. Cassandra Pratt
Chief Human Resources Officer
Ms. Julie Stadlbauer
Chief Business Development Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

PGNY Stock Analysis - Frequently Asked Questions

Should I buy or sell Progyny stock right now?: 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Progyny in the last year. There are currently 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PGNY shares.
View PGNY analyst ratings or view top-rated stocks.
What is Progyny's stock price target for 2024?: 10 brokerages have issued twelve-month price targets for Progyny's shares. Their PGNY share price targets range from $43.00 to $57.00. On average, they predict the company's share price to reach $48.30 in the next year. This suggests a possible upside of 47.5% from the stock's current price.
View analysts price targets for PGNY or view top-rated stocks among Wall Street analysts.
How have PGNY shares performed in 2024?: Progyny's stock was trading at $37.18 on January 1st, 2024. Since then, PGNY stock has decreased by 11.9% and is now trading at $32.75.
View the best growth stocks for 2024 here.
When is Progyny's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our PGNY earnings forecast.
How were Progyny's earnings last quarter?: Progyny, Inc. (NASDAQ:PGNY) issued its earnings results on Tuesday, February, 27th. The company reported $0.13 earnings per share for the quarter, beating analysts' consensus estimates of $0.09 by $0.04. The firm earned $269.94 million during the quarter, compared to analyst estimates of $274.08 million. Progyny had a trailing twelve-month return on equity of 12.64% and a net margin of 5.70%. The firm's revenue was up 26.0% on a year-over-year basis. During the same period in the prior year, the firm earned $0.03 EPS.
What ETFs hold Progyny's stock?: ETFs with the largest weight of Progyny (NASDAQ:PGNY) stock in their portfolio include Alger Weatherbie Enduring Growth ETF (AWEG), Janus Henderson Small Cap Growth Alpha ETF (JSML), BNY Mellon Women's Opportunities ETF (BKWO), SPDR S&P Health Care Services ETF (XHS), Harbor Corporate Culture Small Cap ETF (HAPS), Thrivent Small-Mid Cap ESG ETF (TSME), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG) and AdvisorShares Alpha DNA Equity Sentiment ETF (SENT).

What guidance has Progyny issued on next quarter's earnings?: Progyny issued an update on its first quarter 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share guidance of 0.330-0.350 for the period, compared to the consensus earnings per share estimate of 0.180. The company issued revenue guidance of $285.0 million-$292.0 million, compared to the consensus revenue estimate of $314.0 million.
What is David Schlanger's approval rating as Progyny's CEO?: 25 employees have rated Progyny Chief Executive Officer David Schlanger on Glassdoor.com. David Schlanger has an approval rating of 89% among the company's employees.
What other stocks do shareholders of Progyny own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Progyny investors own include NVIDIA (NVDA), Alibaba Group (BABA), Salesforce (CRM), Marvell Technology (MRVL), Alteryx (AYX), Micron Technology (MU), AbbVie (ABBV), Home Depot (HD), Advanced Micro Devices (AMD).
When did Progyny IPO?: Progyny (PGNY) raised $150 million in an initial public offering (IPO) on Friday, October 25th 2019. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch served as the underwriters for the IPO and Citigroup, Piper Jaffray, SVB Leerink and TPG Capital were co-managers.
Who are Progyny's major shareholders?: Progyny's stock is owned by many different institutional and retail investors. Top institutional investors include Congress Asset Management Co. MA (1.05%), International Assets Investment Management LLC (0.16%), Los Angeles Capital Management LLC (0.05%), Radnor Capital Management LLC (0.04%), NBC Securities Inc. (0.03%) and Financial Management Professionals Inc. (0.00%). Insiders that own company stock include Cheryl Scott, David J Schlanger, Group Holdings (Sbs) Advis Tpg, Jennifer Bealer, Kevin K Gordon, Mark S Livingston, Michael E Sturmer, Norman Payson, Peter Anevski, Robert Michael Floyd and Tpg Gp A, Llc.
View institutional ownership trends.
How do I buy shares of Progyny?: Shares of PGNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PGNY) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Progyny (PGNY) Stock Price, News & Analysis

Progyny MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Progyny Stock (NASDAQ:PGNY)

PGNY Stock Price History

PGNY Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

PGNY Stock Analysis - Frequently Asked Questions

Overall MarketRank^™